Senti Biosciences (NASDAQ:SNTI) Price Target Cut to $11.00 by Analysts at Chardan Capital

Senti Biosciences (NASDAQ:SNTI) had its price target decreased by investment analysts at Chardan Capital from $13.00 to $11.00 in a report released on Monday,Benzinga reports. The firm currently has a “buy” rating on the stock.

Other equities analysts also recently issued research reports about the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Senti Biosciences in a report on Thursday, January 22nd. Wall Street Zen raised shares of Senti Biosciences from a “strong sell” rating to a “hold” rating in a research report on Saturday. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $8.50.

Senti Biosciences Stock Performance

Senti Biosciences stock opened at $0.79 on Monday. Senti Biosciences has a fifty-two week low of $0.79 and a fifty-two week high of $5.10. The stock’s 50 day simple moving average is $0.95 and its two-hundred day simple moving average is $1.38. The stock has a market cap of $20.77 million, a price-to-earnings ratio of -0.25 and a beta of 2.12.

Senti Biosciences (NASDAQ:SNTI) last announced its earnings results on Friday, March 27th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.10). The firm had revenue of $0.02 million during the quarter, compared to analysts’ expectations of $1.00 million. On average, analysts predict that Senti Biosciences will post -14.54 earnings per share for the current year.

Institutional Investors Weigh In On Senti Biosciences

Several hedge funds have recently added to or reduced their stakes in the stock. Jane Street Group LLC purchased a new stake in shares of Senti Biosciences in the fourth quarter worth $40,000. Virtu Financial LLC purchased a new position in shares of Senti Biosciences in the 4th quarter worth about $46,000. Citadel Advisors LLC purchased a new position in shares of Senti Biosciences in the 3rd quarter worth about $117,000. Geode Capital Management LLC boosted its stake in Senti Biosciences by 395.6% in the 2nd quarter. Geode Capital Management LLC now owns 147,314 shares of the company’s stock worth $311,000 after purchasing an additional 117,588 shares in the last quarter. Finally, Armistice Capital LLC purchased a new stake in Senti Biosciences during the 2nd quarter valued at about $1,883,000. 25.70% of the stock is owned by institutional investors.

About Senti Biosciences

Senti Biosciences (NASDAQ:SNTI) is a clinical-stage synthetic biology company focused on engineering next-generation cell therapies. The company’s platform leverages modular genetic circuits to sense disease signals and precisely control cellular functions, with the goal of improving safety and efficacy in oncology and immune-mediated diseases.

Senti’s core technologies include its SENTINEL circuit platform and SNIP receptor system, which enable programmable sensing of molecular cues and context-dependent payload release.